Clinical Labs of Hawaii provides test updates for educational purposes to physicians, specialists, and the general public.
Effective immediately, the Respiratory Panel, PCR (PLA 0202U) and Gastrointestinal (GI) Panel, PCR (PLA 0097U) will no longer be offered as outpatient tests.
Effective March 22, 2022, the HRSA program will no longer accept claims for COVID-19 testing and treatment for uninsured patients.
Effective February 1, 2022, Clinical Labs of Hawaii will be transitioning to a new molecular platform for Influenza A and B testing.
Effective January 7th, 2022, Clinical Labs of Hawaii (CLH) will be updating COVID-19 alert protocol. Due to the significant increase in COVID-19 positives and the improved ability for healthcare providers and patients to receive results in real-time via electronic methods, CLH will discontinue automatically calling COVID-19 positives to the ordering provider.
In response to recommendations from the National Kidney Foundation and American Society of Nephrology (NKF- ASN) Task Force on estimated glomerular filtration rate (eGFR), effective December 12, 2021, Clinical Labs of Hawaii will adopt the single refitted CKD-EPI equation for all serum creatinine measures.
Effective October 25, 2021, Clinical Labs of Hawaii will be transitioning to the Abbott ID NOW ™ molecular platform for the detection of nucleic acid from Streptococcus pyogenes (Group A Streptococcus).
A chart containing Clinical Labs of Hawaii's most common specimen collection media with information on applicable tests and storage.
Effective September 15, 2021, Clinical Labs will be transitioning to a new molecular platform for respiratory syncytial virus testing.
Effective September 13, 2021 Clinical Labs of Hawaii will be offering 25(OH) Vitamin D (Total) testing at our CLH Heights laboratory.
Clinical Labs of Hawaii will be transitioning to the Sysmex UN-Series, a new, automated urinalysis platform.
Effective June 21, 2021, Clinical Labs of Hawaii will be transitioning to the ten-color BD FACSLyric™ Flow Cytometry System as part of our ongoing commitment to excellence.
CLH now offers two serological (antibody) assays to support clinical evaluation of patients who may have been previously infected or exposed to SARS-CoV-2.
Effective March 1, 2021, Clinical Labs of Hawaii will be performing Clostridium difficile testing on the Xpert® C. difficile/Epi.
Effective 10/31/2020, Clinical Labs will no longer offer the Streptozyme test (STRZ). The manufacturer is no longer producing the test and no replacement has been offered.